findmyKOL
Clinical trialNCT05436535CompletedPhase 4Interventional

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment433Atopic Dermatitis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment. Participants will complete up to ten scheduled study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected at all study visits to determine the gene expression profiles and transcriptomic endotypes that underlie mild vs. moderate-severe AD disease. The investigators will also evaluate the lipidomic, metabolomic, proteomic, and microbiome profiles of AD skin endotypes associated with mild and moderate-severe AD disease. Non-AD participants will serve as a control population. The primary objective of this study is to determine if the type 2-high non-lesional skin (skin tape) endotype is associated with current mild versus moderate-severe AD disease.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Donald Leung, M.D., Ph.D.

    National Jewish Health: Division of Pediatric Allergy and Clinical Immunology

    Study Chair
  • Max A. Seibold, Ph.D.

    National Jewish Health: Division of Pediatric Allergy and Clinical Immunology

    Study Chair

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of California, San Diego: Dermatology Clinical Trials Unit

    La Jolla, California, United States

  • Children'S Hospital Los Angeles: Division of Clinical Immunology & Allergy

    Los Angeles, California, United States

  • National Jewish Health: Division of Pediatric Allergy and Clinical Immunology

    Denver, Colorado, United States

  • Boston Children'S Hospital: Department of Immunology

    Boston, Massachusetts, United States

  • Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology

    New York, New York, United States

  • University of Rochester Medical Center: Department of Dermatology

    Rochester, New York, United States

  • North Carolina Children'S Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology

    Chapel Hill, North Carolina, United States

  • Cincinnati Children'S Hospital Medical Center: Asthma Center

    Cincinnati, Ohio, United States

  • Oregon Health & Science University: Department of Dermatology

    Portland, Oregon, United States

  • University of Pennsylvania, Perelman Center for Advanced Medicine: Department of Dermatology

    Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dupilumab →Hydrocortisone / lactate →Triamcinolone →Vanicream- ActiveVanicream- Dupilumab-naïveVanicream- Experienced Dupilumab
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
21 Nov 2022
Primary completion
7 Apr 2025
Completion
24 Oct 2025
Last update posted
4 Jun 2026
Registered enrollment
433
Registry id
NCT05436535

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.